Section Arrow
LXEO.NASDAQ
- Lexeo Therapeutics
Quotes are at least 15-min delayed:2026/05/21 02:28 EDT
Regular Hours
Last
 5.12
+0.64 (+14.29%)
Day High 
5.2 
Prev. Close
4.48 
1-M High
6.95 
Volume 
1.83M 
Bid
5.12
Ask
5.56
Day Low
4.48 
Open
4.48 
1-M Low
4.435 
Market Cap 
351.78M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 5.52 
20-SMA 5.69 
50-SMA 5.97 
52-W High 10.99 
52-W Low 2.5109 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.12/0.78
Enterprise Value
356.99M
Balance Sheet
Book Value Per Share
2.95
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
0.01
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
SLXNSilexion Therapeutics Corp0.5298+0.2608+96.95%-- 
JUNSJupiter Neurosciences Inc0.205-0.115-35.94%-- 
PHGEBiomX Inc.0.5969+0.2229+59.60%-- 
HCWBHCW Biologics Inc2.43+1.37+129.25%-- 
MTVAMetaVia Inc.2.89+1.01+53.72%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases. The company is advancing a portfolio of programs focused on conditions such as Friedreich ataxia, cardiomyopathy, plakophilin-2, or PKP2, and arrhythmogenic cardiomyopathy, with its lead candidates including LX2006 and LX2020. Its therapies utilize AAV-based vectors designed to deliver functional genes to cardiac cells to restore normal function and address high unmet medical needs.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.